{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:54:16Z","timestamp":1790729656318,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology Letters"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.toxlet.2019.09.023","type":"journal-article","created":{"date-parts":[[2019,9,30]],"date-time":"2019-09-30T18:42:27Z","timestamp":1569868947000},"page":"120-129","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Adverse vacuolation in multiple tissues in cynomolgus monkeys following repeat-dose administration of a PEGylated protein"],"prefix":"10.1016","volume":"317","author":[{"given":"Anthony M.","family":"Fletcher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Tellier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Douville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Mansell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Graziano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raja S.","family":"Mangipudy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.","family":"Brodie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William E.","family":"Achanzar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.toxlet.2019.09.023_bib0005","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/cncr.22739","article-title":"Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients","volume":"110","author":"Armstrong","year":"2007","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.toxlet.2019.09.023_bib0010","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/toxsci\/42.2.152","article-title":"Short communication: renal tubular vacuolation in animals treated with polyethylene-glycol-conjugated proteins","volume":"42","author":"Bendele","year":"1998","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.toxlet.2019.09.023_bib0015","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.yrtph.2016.08.012","article-title":"Non-clinical safety evaluation of biotherapeutics \u2013 challenges, opportunities and new insights","volume":"80S","author":"Blaich","year":"2016","journal-title":"Regul. Toxicol. Pharmacol."},{"issue":"1","key":"10.1016\/j.toxlet.2019.09.023_bib0020","first-page":"376","article-title":"Cytoplasmic vacuoles in renal tubular epithelium of mice given polyethylene glycol (PEG) conjugated protein are reduced by altering peg size and conformation","volume":"60","author":"Bolon","year":"2001","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.toxlet.2019.09.023_bib0025","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1146\/annurev.pharmtox.010909.105547","article-title":"Discovery and development of therapeutic aptamers","volume":"50","author":"Bouchard","year":"2010","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"10","key":"10.1016\/j.toxlet.2019.09.023_bib0030","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S0169-409X(03)00108-X","article-title":"Pharmacokinetic and biodistribution properties of poly(ethylene glycol) \u2013 protein conjugates","volume":"55","author":"Caliceti","year":"2003","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.toxlet.2019.09.023_bib0035","series-title":"EMA\u2019s Paediatric Committee Regarding the Use of PEGylated Drug Products in the Pediatric Population Intended for Long-Term Treatment","author":"CHMP Safety Working Party of the European Medicinal Agency","year":"2012"},{"issue":"2","key":"10.1016\/j.toxlet.2019.09.023_bib0040","first-page":"65","article-title":"Drug review - Pegasys (peginterferon alfa-2a [40kDal])","volume":"3","author":"Clark","year":"2007","journal-title":"Drugs Context"},{"issue":"6","key":"10.1016\/j.toxlet.2019.09.023_bib0045","doi-asserted-by":"crossref","first-page":"599","DOI":"10.3109\/10731199609118885","article-title":"Transitional vacuole formation following a bolus infusion of PEG-hemoglobin in the rat","volume":"24","author":"Conover","year":"1996","journal-title":"Artif. Cells Blood Substit. Immobil. Biotechnol."},{"issue":"5","key":"10.1016\/j.toxlet.2019.09.023_bib0050","first-page":"238","article-title":"The effects of hemodilution with polyethylene glycol bovine hemoglobin (PEG-Hb) in a conscious porcine model","volume":"44","author":"Conover","year":"1996","journal-title":"J. Invest. Med."},{"issue":"1\u20132","key":"10.1016\/j.toxlet.2019.09.023_bib0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.tox.2005.06.001","article-title":"Safety assessment on polyethylene glycols (PEGs) and their derivatives as used in cosmetic products","volume":"214","author":"Fruijtier-Polloth","year":"2005","journal-title":"Toxicology"},{"issue":"1","key":"10.1016\/j.toxlet.2019.09.023_bib0060","doi-asserted-by":"crossref","first-page":"R12","DOI":"10.1186\/ar1861","article-title":"Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase","volume":"8","author":"Ganson","year":"2006","journal-title":"Arthritis Res. Ther."},{"issue":"11","key":"10.1016\/j.toxlet.2019.09.023_bib0065","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1517\/17425247.2012.720969","article-title":"Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents","volume":"9","author":"Garay","year":"2012","journal-title":"Expert Opin. Drug Deliv."},{"issue":"2","key":"10.1016\/j.toxlet.2019.09.023_bib0070","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1152\/physrev.00055.2006","article-title":"Properties of the glomerular barrier and mechanisms of proteinuria","volume":"88","author":"Haraldsson","year":"2008","journal-title":"Physiol. Rev."},{"issue":"3","key":"10.1016\/j.toxlet.2019.09.023_bib0075","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nrd1033","article-title":"Effect of pegylation on pharmaceuticals","volume":"2","author":"Harris","year":"2003","journal-title":"Nat. Rev. Drug Discov."},{"issue":"7","key":"10.1016\/j.toxlet.2019.09.023_bib0080","doi-asserted-by":"crossref","first-page":"539","DOI":"10.2165\/00003088-200140070-00005","article-title":"Pegylation: a novel process for modifying pharmacokinetics","volume":"40","author":"Harris","year":"2001","journal-title":"Clin. Pharmacokinet."},{"issue":"6","key":"10.1016\/j.toxlet.2019.09.023_bib0085","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1248\/bpb.b13-00107","article-title":"Anti-polyethyleneglycol antibody response to PEGylated substances","volume":"36","author":"Ishida","year":"2013","journal-title":"Biol. Pharm. Bull."},{"issue":"1","key":"10.1016\/j.toxlet.2019.09.023_bib0090","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1365-2516.2012.02931.x","article-title":"PEGylated therapeutic proteins for haemophilia treatment: a review for haemophilia caregivers","volume":"19","author":"Ivens","year":"2013","journal-title":"Haemophilia"},{"issue":"7","key":"10.1016\/j.toxlet.2019.09.023_bib0095","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1177\/0192623315591171","article-title":"PEGylated biopharmaceuticals: current experience and considerations for nonclinical development","volume":"43","author":"Ivens","year":"2015","journal-title":"Toxicol. Pathol."},{"issue":"1","key":"10.1016\/j.toxlet.2019.09.023_bib0100","first-page":"46","article-title":"Microscopic vacuoles reported in US FDA BLA reviews of pegylated proteins were associated with drug accumulation in repeat-dose studies, greater than dose proportional plasma concentrations, and high clinical multiples","volume":"33","author":"Kaufman","year":"2014","journal-title":"Int. J. Toxicol."},{"issue":"29","key":"10.1016\/j.toxlet.2019.09.023_bib0105","doi-asserted-by":"crossref","first-page":"15064","DOI":"10.1016\/S0021-9258(18)68146-3","article-title":"Relationship of effective molecular size to systemic clearance in rats of recombinant interleukin-2 chemically modified with water-soluble polymers","volume":"263","author":"Knauf","year":"1988","journal-title":"J. Biol. Chem."},{"issue":"36","key":"10.1016\/j.toxlet.2019.09.023_bib0110","doi-asserted-by":"crossref","first-page":"6288","DOI":"10.1002\/anie.200902672","article-title":"Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives","volume":"49","author":"Knop","year":"2010","journal-title":"Angew. Chem. Int. Ed. Engl."},{"issue":"7","key":"10.1016\/j.toxlet.2019.09.023_bib0115","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2165\/00063030-200115070-00001","article-title":"Development of pegylated interferons for the treatment of chronic hepatitis C","volume":"15","author":"Kozlowski","year":"2001","journal-title":"BioDrugs"},{"issue":"2","key":"10.1016\/j.toxlet.2019.09.023_bib0120","doi-asserted-by":"crossref","first-page":"R60","DOI":"10.1186\/ar4497","article-title":"Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout","volume":"16","author":"Lipsky","year":"2014","journal-title":"Arthritis Res. Ther."},{"issue":"7","key":"10.1016\/j.toxlet.2019.09.023_bib0125","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1002\/jps.23506","article-title":"Biodistribution and excretion of radiolabeled 40\u2009kDa polyethylene glycol following intravenous administration in mice","volume":"102","author":"Longley","year":"2013","journal-title":"J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.toxlet.2019.09.023_bib0130","first-page":"125","article-title":"Modulation of the pharmacokinetics and pharmacodynamics of proteins by polyethylene glycol conjugation","volume":"3","author":"Mehvar","year":"2000","journal-title":"J. Pharm. Sci."},{"issue":"4","key":"10.1016\/j.toxlet.2019.09.023_bib0135","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S0169-409X(02)00022-4","article-title":"Chemistry for peptide and protein PEGylation","volume":"54","author":"Roberts","year":"2002","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"7","key":"10.1016\/j.toxlet.2019.09.023_bib0140","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1177\/0192623312474726","article-title":"High molecular weight polyethylene glycol cellular distribution and PEG-associated cytoplasmic vacuolation is molecular weight dependent and does not require conjugation to proteins","volume":"41","author":"Rudmann","year":"2013","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.toxlet.2019.09.023_bib0145","doi-asserted-by":"crossref","first-page":"481520","DOI":"10.1155\/2012\/481520","article-title":"Mechanisms of glomerular albumin filtration and tubular reabsorption","volume":"2012","author":"Tojo","year":"2012","journal-title":"Int. J. Nephrol."},{"issue":"2","key":"10.1016\/j.toxlet.2019.09.023_bib0150","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.xphs.2015.11.015","article-title":"PEGylation of biopharmaceuticals: a review of chemistry and nonclinical safety information of approved drugs","volume":"105","author":"Turecek","year":"2016","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.toxlet.2019.09.023_bib0155","series-title":"Cimzia, Certolizumab Pegol. FDA Pharmacology Review","author":"US Food and Drug Administration","year":"2008"},{"key":"10.1016\/j.toxlet.2019.09.023_bib0160","series-title":"Palynziq, pegvaliase-pqpd. FDA BLA Multi-Disciplinary Review and Evaluation","author":"US Food and Drug Administration","year":"2018"},{"issue":"1","key":"10.1016\/j.toxlet.2019.09.023_bib0165","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s00424-009-0638-2","article-title":"Kidney amino acid transport","volume":"458","author":"Verrey","year":"2009","journal-title":"Pflug. Arch."},{"issue":"1","key":"10.1016\/j.toxlet.2019.09.023_bib0170","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1124\/dmd.106.012419","article-title":"PEGylated proteins: evaluation of their safety in the absence of definitive metabolism studies","volume":"35","author":"Webster","year":"2007","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.toxlet.2019.09.023_bib0175","series-title":"PEGylated Protein Drugs: Basic Science and Clinical Applications","first-page":"127","article-title":"PEG and PEG conjugates toxicity: towards an understanding of the toxicity of PEG and its relevance to PEGylated biologicals","author":"Webster","year":"2009"},{"issue":"4","key":"10.1016\/j.toxlet.2019.09.023_bib0180","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/jps.2600830432","article-title":"Distribution and tissue uptake of poly(ethylene glycol) with different molecular weights after intravenous administration to mice","volume":"83","author":"Yamaoka","year":"1994","journal-title":"J. Pharm. Sci."},{"issue":"10","key":"10.1016\/j.toxlet.2019.09.023_bib0185","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1093\/protein\/gzg093","article-title":"Tailoring structure-function and pharmacokinetic properties of single-chain Fv proteins by site-specific PEGylation","volume":"16","author":"Yang","year":"2003","journal-title":"Protein Eng."},{"issue":"6","key":"10.1016\/j.toxlet.2019.09.023_bib0190","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.trsl.2006.09.007","article-title":"Toxicity and hemodynamic effects after single dose administration of malPEG-hemoglobin (MP4) in rhesus monkeys","volume":"149","author":"Young","year":"2007","journal-title":"Transl. Res."},{"issue":"3","key":"10.1016\/j.toxlet.2019.09.023_bib0195","first-page":"335","article-title":"Discussion about several potential drawbacks of PEGylated therapeutic proteins","volume":"37","author":"Zhang","year":"2014","journal-title":"S100"}],"container-title":["Toxicology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378427419302929?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378427419302929?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T05:17:33Z","timestamp":1759900653000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378427419302929"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":39,"alternative-id":["S0378427419302929"],"URL":"https:\/\/doi.org\/10.1016\/j.toxlet.2019.09.023","relation":{},"ISSN":["0378-4274"],"issn-type":[{"value":"0378-4274","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adverse vacuolation in multiple tissues in cynomolgus monkeys following repeat-dose administration of a PEGylated protein","name":"articletitle","label":"Article Title"},{"value":"Toxicology Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.toxlet.2019.09.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}